Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · IEX Real-Time Price · USD
8.60
0.00 (0.00%)
At close: May 3, 2024, 4:00 PM
8.22
-0.38 (-4.42%)
After-hours: May 3, 2024, 7:53 PM EDT
Arcutis Biotherapeutics Revenue
In the year 2023, Arcutis Biotherapeutics had annual revenue of $59.61M with 1,517.09% growth. Revenue in the quarter ending December 31, 2023 was $13.53M with 356.81% year-over-year growth.
Revenue (ttm)
$59.61M
Revenue Growth
+1,517.09%
P/S Ratio
15.43
Revenue / Employee
$201,372
Employees
296
Market Cap
919.77M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioCryst Pharmaceuticals | 331.41M |
| Canopy Growth | 248.53M |
| Standard BioTools | 106.34M |
| Simulations Plus | 64.67M |
| Ocular Therapeutix | 58.44M |
| Relay Therapeutics | 35.33M |
| Abivax | 5.13M |
ARQT News
- 2 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 - GlobeNewsWire
- 25 days ago - Arcutis Appoints David Topper as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - VKTX, JANX and these biotech stocks are surging in 2024 - Invezz
- 5 weeks ago - Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Arcutis Promotes Todd Tucker to Chief Human Resources Officer - GlobeNewsWire
- 2 months ago - Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting - GlobeNewsWire